HOXA1, a breast cancer oncogene

Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188747. doi: 10.1016/j.bbcan.2022.188747. Epub 2022 Jun 5.

Abstract

More than 25 years ago, the first literature records mentioned HOXA1 expression in human breast cancer. A few years later, HOXA1 was confirmed as a proper oncogene in mammary tissue. In the following two decades, molecular data about the mode of action of the HOXA1 protein, the factors contributing to activate and maintain HOXA1 gene expression and the identity of its target genes have accumulated and provide a wider view on the association of this transcription factor to breast oncogenesis. Large-scale transcriptomic data gathered from wide cohorts of patients further allowed refining the relationship between breast cancer type and HOXA1 expression. Several recent reports have reviewed the connection between cancer hallmarks and the biology of HOX genes in general. Here we take HOXA1 as a paradigm and propose an extensive overview of the molecular data centered on this oncoprotein, from what its expression modulators, to the interactors contributing to its oncogenic activities, and to the pathways and genes it controls. The data converge to an intricate picture that answers questions on the multi-modality of its oncogene activities, point towards better understanding of breast cancer aetiology and thereby provides an appraisal for treatment opportunities.

Keywords: Estrogen receptor; HOX genes; HOXA1; Regulatory network; breast cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / metabolism
  • Cell Transformation, Neoplastic / genetics
  • Female
  • Genes, Homeobox*
  • Homeodomain Proteins* / genetics
  • Humans
  • Oncogenes*
  • Transcription Factors* / genetics

Substances

  • Homeodomain Proteins
  • Transcription Factors
  • homeobox A1 protein